Honasa Consumer, Mamaearth's parent, addressed recent allegations, labelling them as "misinformation." This and more in today’s ETtech Top ...

Late last year, Prosus said it had ceased equity accounting of Byju’s as it had lost “significant influence” over the firm after its holdin...

The online pharmacy is also in talks to restructure debt terms ahead of rights issue; share sale set to open on September 4

Goldman Sachs is likely to convert some of its loan to online pharmacy PharmEasy into equity. Buoyed by binding commitments from existing i...

A down round is when a privately held firm raises funds at a valuation lower than that ascribed in the previous round.

This week’s ETtech newsbreak on PharmEasy going for a rights issue at a price 90% lower than its peak valuation of $5.6 billion to repay de...

With the global liquidity situation changing, institutional investors were no longer interested in waiting patiently for startups to go hyb...

Happy Friday! Arokiaswamy Velumani, founder of Thyrocare, which was acquired by PharmEasy in 2021, had secured anti-dilution rights when he...

Happy Friday! Union IT minister Ashwini Vaishnaw told ET in an interview that some major players expect India to be the next chip-making de...

Byju’s woes seem to have no end. The company has suffered a series of setbacks over the last year, including ED raids and valuation markdow...

Centralised Know Your Customer (C-KYC) database, which was conceived as a solution to KYC challenges faced by financial institutions, has b...

Prosus Ventures, Temasek and others participate; online pharmacy reconsidering external fundraise amid funding slowdown

The Mumbai-based firm is also stitching up a private financing round through a rights issue where company founders are expected to invest p...

The money will predominantly be used to refinance the debt the company had taken to fund its acquisition of diagnostics chain Thyrocare las...

IIFL Securities has sold over Rs 100 crore worth of PharmEasy stock to wealthy individuals at Rs 103 a share. Those shares traded at Rs 78 ...

PharmEasy is in talks with a clutch of new investors, including two hedge funds, to join its pre-IPO funding round.

Reliance's yet-to-be announced acquisition of Netmeds for an estimated $120 million is a catalyst for other players such as PharmEasy and M...